Analysis of Adverse Events of Dasatinib and Nilotinib in Chronic Phase Chronic Myeloid Leukemia Patients Treated Outside Clinical Trials

被引：0
|
作者：
Suh, Koung Jin [1 ,2 ]
Lee, Ji Yun [2 ]
Shin, Dong-Yeop [1 ]
Koh, Youngil [1 ]
Bang, Soo-Mee [3 ]
Yoon, Sung-Soo [1 ]
Park, Seonyang [4 ]
Kim, Inho [1 ]
Lee, Jeong-Ok [2 ]
机构：
[1] Seoul Natl Univ Hosp, Internal Med, Seoul, South Korea
[2] Seoul Natl Univ Bundang Hosp, Internal Med, Seongnam, South Korea
[3] Seoul Natl Univ Bundang Hosp, Seongnam, South Korea
[4] Inje Univ, Haeundae Paik Hosp, Internal Med, Busan, South Korea
来源：
BLOOD | 2016年 / 128卷 / 22期
关键词：
D O I：
10.1182/blood.V128.22.1902.1902
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
1902
引用
收藏
页数：4
相关论文
共 50 条
  • [41] SYSTEMATIC REVIEW OF CLINICAL TRIALS AND PROSPECTIVE COHORTS: FOLLOW UP METHODS IN PATIENTS WITH CHRONIC MYELOID LEUKEMIA TREATED WITH DASATINIB
    Grazziotin, L. R.
    Stoll, P.
    Wust, D.
    Hegele, V.
    Ehrembrick, G.
    Caregnato, J.
    Lindenmeyer, L.
    INTERNATIONAL JOURNAL OF PHARMACEUTICAL SCIENCES AND RESEARCH, 2012, 3 (12): : 4710 - 4721
  • [42] Real-life comparison of nilotinib versus dasatinib as second-line therapy in chronic phase chronic myeloid leukemia patients
    Scalzulli, Emilia
    Caocci, Giovanni
    Efficace, Fabio
    Rizzo, Lorenzo
    Colafigli, Gioia
    Di Prima, Alessio
    Pepe, Sara
    Fegatelli, Danilo Alunni
    Carmosino, Ida
    Diverio, Daniela
    Latagliata, Roberto
    La Nasa, Giorgio
    Martelli, Maurizio
    Foa, Robin
    Breccia, Massimo
    ANNALS OF HEMATOLOGY, 2021, 100 (05) : 1213 - 1219
  • [43] Real-life comparison of nilotinib versus dasatinib as second-line therapy in chronic phase chronic myeloid leukemia patients
    Emilia Scalzulli
    Giovanni Caocci
    Fabio Efficace
    Lorenzo Rizzo
    Gioia Colafigli
    Alessio Di Prima
    Sara Pepe
    Danilo Alunni Fegatelli
    Ida Carmosino
    Daniela Diverio
    Roberto Latagliata
    Giorgio La Nasa
    Maurizio Martelli
    Robin Foà
    Massimo Breccia
    Annals of Hematology, 2021, 100 : 1213 - 1219
  • [44] Pregnancy Outcomes among Patients with Chronic Myeloid Leukemia Treated with Dasatinib
    Cortes, Jorge
    O'Brien, Susan
    Ault, Patricia
    Borthakur, Gautam
    Jabbour, Elias
    Bradley-Garelik, Brigid
    Debreczeni, Krisztina
    Yang, Daniel
    Liu, David
    Kantarjian, Hagop
    BLOOD, 2008, 112 (11) : 1109 - 1109
  • [45] Cardiovascular events and atherogenic lipid profile in chronic myeloid leukemia patients treated with nilotinib versus imatinib
    Petrikova, L.
    Slezakova, K.
    Sninska, Z.
    Harvanova, L.
    Martisova, M.
    Hatalova, A.
    Mistrik, M.
    Batorova, A.
    Mladosievicova, B.
    BRATISLAVA MEDICAL JOURNAL-BRATISLAVSKE LEKARSKE LISTY, 2021, 122 (08): : 531 - 537
  • [46] Using Proton Pump Inhibitors is not Associated With Adverse Outcomes in Patients With Chronic Myeloid Leukemia Treated With Dasatinib
    Haddad, Fadi G.
    Nasnas, Cedric
    Sasaki, Koji
    Paul, Shilpa
    Issa, Ghayas C.
    Rausch, Caitlin
    Jabbour, Elias
    Kantarjian, Hagop
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2024, 24 (07): : 484 - 487
  • [47] Evaluation of the Effects of Nilotinib on Platelet Function in Patients with Chronic Myeloid Leukemia in Chronic Phase
    Alqasim, A. M. Z.
    Obaid, G.
    Yaseen, Y.
    Alwan, A.
    BRITISH JOURNAL OF HAEMATOLOGY, 2018, 181 : 195 - 196
  • [48] Long-term bosutinib for chronic phase chronic myeloid leukemia after failure of imatinib plus dasatinib and/or nilotinib
    Cortes, Jorge E.
    Khoury, Hanna J.
    Kantarjian, Hagop M.
    Lipton, Jeff H.
    Kim, Dong-Wook
    Schafhausen, Philippe
    Matczak, Ewa
    Leip, Eric
    Noonan, Kay
    Bruemmendorf, Tim H.
    Gambacorti-Passerini, Carlo
    AMERICAN JOURNAL OF HEMATOLOGY, 2016, 91 (12) : 1206 - 1214
  • [49] Response: upfront nilotinib therapy among patients with chronic myeloid leukemia in chronic phase
    Saydam, Guray
    EXPERT OPINION ON PHARMACOTHERAPY, 2017, 18 (03) : 327 - 328
  • [50] Combination of Asciminib plus Nilotinib or Asciminib plus Dasatinib in Previously Treated Chronic Myeloid Leukemia (CML) Patients: Phase 1 Study Results
    DeAngelo, Daniel J.
    Mauro, Michael J.
    Kim, Dong-Wook
    Cortes, Jorge
    Rea, Delphine
    Hughes, Timothy P.
    Minami, Hironobu
    Breccia, Massimo
    Talpaz, Moshe
    Hochhaus, Andreas
    Goh, Yeow Tee
    Le Coutre, Philipp D.
    Sondhi, Manu
    Mishra, Kaushal
    Hourcade-Potelleret, Florence
    Vanasse, Gary
    Aimone, Paola
    Lang, Fabian
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2019, 19 : S290 - S291
12345